Literature DB >> 32146413

Proteolysis targeting chimeras (PROTACs) for epigenetics research.

Anja Vogelmann1, Dina Robaa2, Wolfgang Sippl2, Manfred Jung3.   

Abstract

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules and allow selective protein degradation by addressing the natural ubiquitin proteasome system. As this new strategy of chemically induced protein degradation can serve as a biological tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins. A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these molecules. In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Keywords:  Drug discovery; Epigenetics; PROTACs; Protein degradation

Mesh:

Substances:

Year:  2020        PMID: 32146413     DOI: 10.1016/j.cbpa.2020.01.010

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  15 in total

Review 1.  Drugging the "undruggable" microRNAs.

Authors:  Dejun Liu; Xinqiang Wan; Xiangxiang Shan; Rengen Fan; Wenzhang Zha
Journal:  Cell Mol Life Sci       Date:  2020-10-14       Impact factor: 9.261

2.  The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.

Authors:  Alison M Kurimchak; Carlos Herrera-Montávez; Sara Montserrat-Sangrà; Daniela Araiza-Olivera; Jianping Hu; Ryan Neumann-Domer; Mathew Kuruvilla; Alfonso Bellacosa; Joseph R Testa; Jian Jin; James S Duncan
Journal:  Sci Signal       Date:  2022-08-30       Impact factor: 9.517

Review 3.  Major Advances in Emerging Degrader Technologies.

Authors:  Hang Luo; Li Wu; Yujian He; Chong Qin; Xinjing Tang
Journal:  Front Cell Dev Biol       Date:  2022-06-22

4.  Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.

Authors:  Anand Divakaran; Cole R Scholtz; Huda Zahid; Wenwei Lin; Elizabeth C Griffith; Richard E Lee; Taosheng Chen; Daniel A Harki; William C K Pomerantz
Journal:  ACS Med Chem Lett       Date:  2022-09-29       Impact factor: 4.632

Review 5.  The language of chromatin modification in human cancers.

Authors:  Shuai Zhao; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2021-05-17       Impact factor: 60.716

Review 6.  Molecular Epigenetics: Chemical Biology Tools Come of Age.

Authors:  John D Bagert; Tom W Muir
Journal:  Annu Rev Biochem       Date:  2021-06-20       Impact factor: 27.258

Review 7.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine.

Authors:  Dhanusha A Nalawansha; Craig M Crews
Journal:  Cell Chem Biol       Date:  2020-08-13       Impact factor: 9.039

Review 8.  Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.

Authors:  Ana Rita Cardoso; João Lobo; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2020-08-12       Impact factor: 4.528

9.  Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).

Authors:  Laura Sinatra; Jan J Bandolik; Martin Roatsch; Melf Sönnichsen; Clara T Schoeder; Alexandra Hamacher; Andrea Schöler; Arndt Borkhardt; Jens Meiler; Sanil Bhatia; Matthias U Kassack; Finn K Hansen
Journal:  Angew Chem Int Ed Engl       Date:  2020-10-09       Impact factor: 15.336

Review 10.  Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin.

Authors:  Thijs C J Verheul; Van Tuan Trinh; Olalla Vázquez; Sjaak Philipsen
Journal:  ChemMedChem       Date:  2020-11-04       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.